01 / PARTNERING
Interest without conversion.
Repeated meetings can look productive while the same unspoken evidence issue prevents an asset from crossing an internal strategic threshold.
Confidential Oncology Transaction Practice
Turn strategic uncertainty into a transaction-ready asset.
TSCIP helps clinical-stage oncology companies determine what evidence will change a real strategic decision, align development and capital around that evidence, and re-enter partnering discussions with a stronger asset.
Why TSCIP
The problem is often not lack of interest. It is unresolved uncertainty.
Clinical assets can attract scientific interest and still fail to convert into a transaction. TSCIP focuses on the specific uncertainty that keeps a partner, board or capital provider from acting.
02 / EVIDENCE
Data without decision value.
More development is not automatically better development. The highest-value next study is the one that answers the question capable of changing a real decision.
03 / CAPITAL
Runway without an inflection thesis.
Capital becomes more strategic when it is tied to a bounded evidence tranche and a defined decision point—not simply another period of operating runway.
How TSCIP works
A confidential transaction practice built around the next strategic decision.
The public workflow is intentionally simple. TSCIP keeps its scoring, selection logic, counterparty intelligence and evidence-design architecture private.
01
Cover
TSCIP selects clinical assets for coverage from the oncology landscape. Coverage is curated by TSCIP; it is not a paid listing or open self-service marketplace.
02
Diagnose
Current clinical evidence is translated into the strategic uncertainty most likely to prevent a licensing, investment, co-development or other transaction decision.
03
Validate
Relevant external decision requirements are tested confidentially. Buyer-side searches, views, saves, passes and private requirements are not exposed to asset owners.
04
Advance
Asset owners receive a focused evidence, development, capital-to-inflection and transaction-readiness path designed to support the next strategic decision.
Confidential by design
Decision intelligence without buyer surveillance.
TSCIP is not an open marketplace. Pharma and other strategic evaluators can review curated opportunities privately. Asset owners receive synthesized TSCIP decision outputs—not a feed of who searched, viewed, saved, passed or expressed a private requirement.
Identity stays controlled
Buyer identity is released only with explicit consent. Internal scoring rules, asset-ranking methods, counterparty-selection logic, decision thresholds and evidence-design architecture remain proprietary to TSCIP.
One decision layer
Partnering, evidence and capital converge on one value inflection.
TSCIP connects work that is usually fragmented across BD, clinical development and financing. The objective is not to maximize activity; it is to create the smallest credible path to a strategic decision.
01
Strategic Partnering
Clarify what must change for a credible counterparty to advance, then structure re-engagement around that decision rather than another generic BD follow-up.
02
Evidence Architecture
Define a bounded evidence tranche capable of resolving the key uncertainty while avoiding unnecessary development breadth, cost and time.
03
Capital-to-Inflection
Align the amount, timing and form of capital with the evidence milestone it is meant to purchase. Capital enables the decision; it is not the core TSCIP product.
Strategic & structured capital
Finance the evidence that can change the decision.
TSCIP may help management compare strategic investment, co-development, licensing, royalty, asset-level and other structured alternatives around a defined value inflection. Capital-side visibility is limited to owner-authorized opportunities.
Strategic investment
Co-development funding
Regional licensing
Option structures
Royalty monetization
Asset-level financing
Structured debt
Illustrative pharma venture organizations
Pfizer Ventures · Sanofi Ventures · Johnson & Johnson Innovation – JJDC
Illustrative royalty / structured-capital organizations
Royalty Pharma · HealthCare Royalty (HCRx) · DRI Healthcare
Independent market examples only.
The organizations named above are public examples of participants in the life-sciences
capital ecosystem. TSCIP and Nectid have no affiliation, endorsement, partnership, agency,
referral arrangement or other relationship with them unless separately and expressly disclosed in writing.
Role boundary: TSCIP and Nectid provide strategic advisory, diligence and
decision-support services. They are not broker-dealers, placement agents, investment banks or
securities intermediaries; they do not offer or sell securities, handle investor funds, or receive
transaction-based compensation for securities placements. Securities placement activity should be
conducted directly by the company or through an appropriately registered intermediary.
Who TSCIP serves
Three sides of the transaction. Different information rights.
TSCIP is designed to move clinical assets toward a strategic decision while protecting the confidentiality and incentives of each participant.
Asset owners
Receive TSCIP-authored decision outputs that identify the evidence and development actions most likely to improve transaction readiness.
- Partnerability assessment
- Evidence gate
- Development action
- Capital-to-inflection
- Transaction readiness
- Next action
Pharma & strategic buyers
Review curated opportunities privately without creating a marketplace signal or exposing internal search behavior to asset owners.
- Private asset review
- Confidential searches and saves
- Private decision requirements
- No owner-side buyer surveillance
- Identity released only by consent
Development-capital providers
Review owner-authorized opportunities where a bounded evidence tranche could create a strategic decision point and a clearer capital-use thesis.
- Defined use of capital
- Evidence-linked milestones
- Decision-focused diligence
- Owner-authorized visibility
- No securities placement by TSCIP
TSCIP worked case · PDS0301
From a recurring evidence gap to milestone-linked strategic financing.
PDS0301 illustrates the TSCIP model: repeated strategic evaluations converged on a specific contribution question, the development path was reframed around that issue, and capital was aligned with the next evidence milestone.
Public outcome announced September 8, 202601
Repeated interest, recurring evidence issue
Across strategic evaluations, de-identified feedback converged on a recurring question: whether PDS0301's independent contribution to observed combination activity was sufficiently clear for counterparties to underwrite the next step.
02
TSCIP translated feedback into an evidence gate
Rather than treating every counterparty response as an isolated BD outcome or defaulting to broad additional development, the recurring requirement was translated into a bounded evidence and late-stage development path.
03
Capital was framed around the inflection
Within the TSCIP engagement, the financing requirement was organized around reaching a defined development milestone and closing the strategic evidence gap—not simply extending runway.
04
Public outcome: up to $22.55M strategic financing
On September 8, 2026, PDS Biotech announced up to $22.55 million in PIPE financing led by Nant Capital. The structure included approximately $11.55 million at the initial closing and an additional $11 million contingent milestone closing tied to submission of a registrational Phase 3 protocol for PDS0301. Nant also received board-designation rights, including Dr. Patrick Soon-Shiong.
Important context: Public financing terms above are from PDS Biotech's
September 8, 2026 announcement. That announcement does not attribute the financing to TSCIP.
The description of TSCIP's role reflects the TSCIP engagement and is presented to illustrate
the workflow; it should not be read as a claim that TSCIP was the sole cause of the financing.
Additional transaction experience
A longer history of translating differentiated assets into strategic value.
TSCIP builds on Nectid's prior experience creating therapeutic IP, positioning it for a strategic counterparty and carrying that work into a completed transaction.
Nectid-originated therapeutic IP → Grünenthal GmbH
A patent portfolio originating from Nectid was later acquired by Grünenthal. The historical precedent matters because it reflects the same discipline behind TSCIP today: differentiated thesis, defensibility, strategic fit and transaction execution.
Public transaction
2011
About TSCIP
Decision infrastructure for oncology transactions.
TSCIP
A confidential oncology transaction practice developed and operated by Nectid
TSCIP combines clinical-asset intelligence, biotechnology business development, confidential external validation and evidence-to-decision strategy.
It is intentionally not an open marketplace. Assets enter coverage by TSCIP selection, not by paid listing, and buyer-side activity remains private unless a counterparty explicitly chooses to engage.
TSCIP supports licensing, options, co-development, strategic investment, financing, carve-outs and other transaction paths while keeping its internal scoring and decision architecture proprietary.
TSCIP is a proprietary practice of Nectid.
Contact
Have a clinical asset with interest—but no clear transaction path?
Start with the strategic decision you are trying to unlock. Initial conversations should stay non-confidential until both sides agree otherwise.